These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 36510261

  • 21. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.
    Zubizarreta I, Flórez-Grau G, Vila G, Cabezón R, España C, Andorra M, Saiz A, Llufriu S, Sepulveda M, Sola-Valls N, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Casanova B, Martinez Gines M, Tellez N, Oreja-Guevara C, Español M, Trias E, Cid J, Juan M, Lozano M, Blanco Y, Steinman L, Benitez-Ribas D, Villoslada P.
    Proc Natl Acad Sci U S A; 2019 Apr 23; 116(17):8463-8470. PubMed ID: 30962374
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Recent discoveries in dendritic cell tolerance-inducing pharmacological molecules.
    Švajger U, Rožman PJ.
    Int Immunopharmacol; 2020 Apr 23; 81():106275. PubMed ID: 32044665
    [Abstract] [Full Text] [Related]

  • 27. Dendritic cells and multiple sclerosis: disease, tolerance and therapy.
    Mohammad MG, Hassanpour M, Tsai VW, Li H, Ruitenberg MJ, Booth DW, Serrats J, Hart PH, Symonds GP, Sawchenko PE, Breit SN, Brown DA.
    Int J Mol Sci; 2012 Dec 27; 14(1):547-62. PubMed ID: 23271370
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling.
    Barroso A, Mahler JV, Fonseca-Castro PH, Quintana FJ.
    Curr Opin Immunol; 2021 Jun 27; 70():33-39. PubMed ID: 33607496
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance.
    Lin G, Wang J, Yang YG, Zhang Y, Sun T.
    Front Bioeng Biotechnol; 2023 Jun 27; 11():1242126. PubMed ID: 37877041
    [Abstract] [Full Text] [Related]

  • 40. Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis.
    Li R, Li H, Yang X, Hu H, Liu P, Liu H.
    Front Immunol; 2022 Jun 27; 13():970508. PubMed ID: 36177043
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.